Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Christen U(2004)Initiation of autoimmunity Curr. Opin. Immunol. 16 759-767

von Herrath MG(2007)CD3-specific antibodies: a portal to the treatment of autoimmunity Nat. Rev. Immunol. 7 622-632

Chatenoud L(2005)Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease Int. Rev. Immunol. 24 361-392

Bluestone JA(2007)Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease Nat. Rev. Immunol. 7 665-677

Kohm AP(2009)Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin. Immunol. 132 166-173

Turley DM(2000)Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand Nat. Med. 6 1167-1175

Miller SD(2012)Evolution of MS lesions to black holes under DNA vaccine treatment J. Neurol. 259 1375-1382

Miller SD(2011)A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS Neurology 77 1551-1560

Turley DM(2005)Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis Proc. Natl. Acad. Sci. USA 102 9595-9600

Podojil JR(2000)Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis J. Immunol. 164 670-678

Christen U(2004)Initiation of autoimmunity Curr. Opin. Immunol. 16 759-767

von Herrath MG(2007)CD3-specific antibodies: a portal to the treatment of autoimmunity Nat. Rev. Immunol. 7 622-632

Chatenoud L(2005)Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease Int. Rev. Immunol. 24 361-392

Bluestone JA(2007)Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease Nat. Rev. Immunol. 7 665-677

Kohm AP(2009)Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin. Immunol. 132 166-173

Turley DM(2000)Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand Nat. Med. 6 1167-1175

Miller SD(2012)Evolution of MS lesions to black holes under DNA vaccine treatment J. Neurol. 259 1375-1382

Miller SD(2011)A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS Neurology 77 1551-1560

Turley DM(2005)Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis Proc. Natl. Acad. Sci. USA 102 9595-9600

Podojil JR(2000)Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis J. Immunol. 164 670-678